GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoMed Pharmaceuticals Inc (NAS:OMED) » Definitions » Equity-to-Asset

OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Equity-to-Asset : 0.74 (As of Dec. 2018)


View and export this data going back to 2013. Start your Free Trial

What is OncoMed Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OncoMed Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2018 was $48.23 Mil. OncoMed Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2018 was $65.08 Mil. Therefore, OncoMed Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2018 was 0.74.

The historical rank and industry rank for OncoMed Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

OMED's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

OncoMed Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for OncoMed Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoMed Pharmaceuticals Equity-to-Asset Chart

OncoMed Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.31 0.02 -0.12 -0.44 0.74

OncoMed Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 0.49 0.51 0.67 0.74

Competitive Comparison of OncoMed Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, OncoMed Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoMed Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoMed Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where OncoMed Pharmaceuticals's Equity-to-Asset falls into.



OncoMed Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

OncoMed Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Equity to Asset (A: Dec. 2018 )=Total Stockholders Equity/Total Assets
=48.231/65.078
=0.74

OncoMed Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2018 is calculated as

Equity to Asset (Q: Dec. 2018 )=Total Stockholders Equity/Total Assets
=48.231/65.078
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoMed Pharmaceuticals  (NAS:OMED) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


OncoMed Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of OncoMed Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
800 Chesapeake Drive, Redwood City, CA, USA, 94063
OncoMed Pharmaceuticals Inc is a clinical-stage biotechnology company. The aim of the company is to address cancer initiation, growth, metastases, and recurrence by developing alternative therapies to fight cancer. Its core therapy uses monoclonal antibodies targeting cancer stem cells. The company has strategic alliances with Celgene, Bayer Pharma, and GlaxoSmithKline.
Executives
Perry A Karsen director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Jack W Lasersohn director 18 BANK STREET, SUMMIT NJ 07901
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Rick E Winningham director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Denise Scots-knight director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Sunil Patel officer: See Remarks 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Paul J Hastings officer: Chairman & CEO 61 HARTFORD STREET, SAN FRANCISCO CA 94114
Laurence Lasky director C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jakob Dupont officer: SVP & Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Terry P Gould director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Usvp Entrepreneur Partners Viii A L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Entrepreneur Partners Viii B L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Viii Affiliates Fund L P 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025